We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

and any new IP beyond the three core areas will be available exclusively to CRISPR Therapeutics for human use, and to Bayer for non-human use, such as agricultural applications. Through the JV ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

9 In addition to its application in infectious diseases, there are several CRISPR-based developments for the diagnosis of other diseases, including cancer, where it is being used to detect cancer ...

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

The company's extensive regulatory and technical expertise further bolsters the therapeutic ... access to best-in-class CRISPR solutions at scale, empowering applications from Discovery to Clinic.

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) and rare paediatric disease designation ...